<span item_type="fundamental" item_id="77e8df97c2fafd6bff2f9c53db898100" counter_id="ST/US/RGBP" env="prod"></span><span item_type="announcement" item_id="548206924238102273" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 59.07 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.01.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Net Revenue</strong>: $59,065 for the three months ended June 30, 2025, and $177,195 for the nine months ended June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225022884/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Operating Expenses</strong>: $99,821 for the three months ended June 30, 2025, compared to $167,031 for the same period in 2024. For the nine months ended June 30, 2025, operating expenses were $392,680 compared to $509,013 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225022884/form10-q.htm"></span></li><li><strong>Net Loss</strong>: - $167,292 for the three months ended June 30, 2025, compared to - $130,120 for the same period in 2024. For the nine months ended June 30, 2025, net loss was - $702,033 compared to - $397,507 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225022884/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: - $241,500 for the nine months ended June 30, 2025, compared to - $544,247 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225022884/form10-q.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: $242,545 for the nine months ended June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225022884/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Derivative Liability</strong>: $1,780,402 as of June 30, 2025, compared to $1,404,090 as of September 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225022884/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to continue incurring significant professional costs to remain publicly traded and expects to incur significant research and development costs for product development.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225022884/form10-q.htm"></span></li><li><strong>Liquidity &amp; Capital Resources Outlook</strong>: The company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities to continue operations. Without additional funding, there is substantial doubt about the company’s ability to continue as a going concern for the twelve months from the date of these financial statements.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225022884/form10-q.htm"></span></li></ul>

Regen BioPharma, Inc. | 10-Q: FY2025 Q3 Revenue: USD 59.07 K